Phase I-II Trial of High-Dose Melphalan in Previously Untreated Stage III Multiple Myeloma: Cancer and Leukemia Group B Study 8512

References

• Alexanian R, Bonnert J, Gehan E. Combination chemotherapy for multiple myeloma. Cancer 1972; 30: 382–389
   PubMed Web of Science ®Google Scholar
• Alexanian R, Haut A, Khan A. Treatment for multiple myeloma-combination chemotherapy with different melphalan dose regimens. JAMA 1969; 208: 1680–1685
   PubMed Web of Science ®Google Scholar
• Alexanian R, Blacerzak S, Bonnet I: Prognostic factors in multiple myeloma. Cancer 1975; 36: 1192–1201
   PubMed Web of Science ®Google Scholar
• Cuzick J, Galton D AG, Peto R. Medical Research Council's Working Party on Leukemia in Adults): Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 832–840
   Google Scholar
• Case DC, Jr., Lee BJ JU, Clarkson B D: Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine, and BCNU: M-2 protocol. Am J Med 1977; 63: 897–903
   PubMed Web of Science ®Google Scholar
• Tirelli U, Crivellari D, Carbone A. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmestine (BCNU) (M-2 protocol). Cancer Treat Rep 1971–1973; 66, 1982
   Google Scholar
• Lee B J, Lake-Lewis D, Myers J E. Intensive treatment of multiple myeloma. Controversies in Oncology, PH Wiernick. John Wiley, New York 1982; 61–79
   Google Scholar
• Chronic Leukemia Myeloma Task Force National Institute Cancer. Proposed guidelines for protocol studies 11. Plasma cell myeloma. Cancer Chemother Rep 1973; 4: 145–158
   Google Scholar
• Harley J B, Pajak T F, Mclntyre O R. Improved survival of increased-risk myeloma patients on combined triple-alkylating-agent therapy: A study of the CALGB. Blood 1979; 54: 13–22
   PubMed Web of Science ®Google Scholar
• Bergsagel D E, Bailey A J, Langley G R. The chemotherapy of plasma-cell myeloma and the incidence of acute leukemia. N Engl J Med 1979; 301: 743–748
   PubMed Web of Science ®Google Scholar
• Medical Research Council's Working Party of Leukemia in Adults. Treatment comparisons in the third MRC myelomatosis trial. Br J Cancer 1980; 42: 823–830
   PubMed Web of Science ®Google Scholar
• Salmon S E, Haut A, Bonnet J D. Alternating combination chemotherapy improves survival in multiple myeloma: A Southwest Oncology Group study. J. Clin Oncol 1983; 1: 453–461
   Web of Science ®Google Scholar
• Durie B GM, Dixon D O, Carter S. Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group study. In Process. J Clin Oncol 1986; 4: 1227–1237
   PubMed Web of Science ®Google Scholar
• Oken M M, Tsiatis A, Abramson N. Comparison of standard (MP) with intensive (VBMCP) therapy for the treatment of multiple myeloma (MM). (Abstract) Proc Am Sec Clin Oncol 1984; 3: 270
   Google Scholar
• Coleman M, Silver R. Chemotherapy of plasma cell myeloma and related disorders. Antibiotics and Chemotherapy, HS Griemshed, RW Brockaw, FE Hon. Intercontinental Medical Book Corp., New York 1973; 103–136, Stratton
   Google Scholar
• Case DC, Jr. Future prospects for the therapy of multiple myeloma. Cancer Invest 1989; 7: 243–246
   PubMed Web of Science ®Google Scholar
• McElwain T J, Powles P L. High-dose intravenous melphalan for plasma cell myeloma. Lancet 1983; 2: 822–824
   PubMed Web of Science ®Google Scholar
• Selby P J, McElwain T J, Nandi A C. Multiple myeloma treated with high dose intravenous melphalan. Br J Haematol 1987; 66: 55–62
   PubMed Web of Science ®Google Scholar
• Richards F N, Coleman M, Cooper M R, Ballard W P. Multiple myeloma: Complete remission with high-dose melphalan. Chemother Cancer Invest 1985; 3: 15–21
   PubMed Web of Science ®Google Scholar
• Humphrey R L, Neville S V: High dose cyclophosphamide therapy of patients with poor risk myeloma. Am Soc Chem Oncol (abstr) 1978; 19: 410
   Google Scholar
• Humphrey R L, Kvols L K, Braine H G, Abeloff M D. High dose Cytoxan therapy of poor risk myeloma and Waldenstrom's macroglobulinemia. Am Acad Cancer Res (abstr) 1973; 14: 54
   Web of Science ®Google Scholar
• Case DC, Jr., Coleman M, Gottlieb A: High dose melphalan (HDM) therapy for previously untreated Stage UJ multiple myeloma: a phase I-n study. Blood 1986; 65: 236a
   Google Scholar
• Case DC, Jr., Coleman M, Gottlieb A. High dose melphalan (HDM) therapy for previously untreated Stage III multiple myeloma. Prac Am Soc Clin Oncol 1989; 8: 265
   Google Scholar
• Durie B GM, Salmon S E. A clinical staging system for multiple myeloma. Cancer 1975; 36: 842–854
   PubMed Web of Science ®Google Scholar
• Payne R E, Little A J, Williams R B. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4: 643–646
   PubMed Web of Science ®Google Scholar
• MacLennan I CM, Cuzick J. for the MRC Working Party on leukemia in adults Objective evaluation of the role of vincristine in induction and maintenance for myelomatosis. Br J Cancer 1985; 52: 153–159
   PubMed Web of Science ®Google Scholar
• Greipp P R, Katzmann J A, O'Fallon W M. Value of B2-microglobulin level and plasma cell labeling indices as prognostic factors in patients with newly diagnosed myeloma. Blood 1988; 782: 219–223
   Google Scholar
• Cohen H J, Silberman H R, Forman W. Effects of age on responses to treatment and survival of patients with multiple myeloma. J Am Geriatr Soc 1983; 31: 272–277
   PubMed Web of Science ®Google Scholar
• Cohen H J, Bartolucci A. Age and the treatment of multiple myeloma. Am J Med 1985; 79: 316–324
   PubMed Web of Science ®Google Scholar
• Alexanian R, Jagannath S, Lemaistre F. High dose therapy (HDT) for multiple myeloma. Prac Am Soc Clin Oncol 1989; 8: 270
   Google Scholar
• Gore M E, Mican S, Viner C. Continuous infusion of vincristine and adriamycin with high dose methylprednisolone (VAMP) followed by high dose melphalan (HDM) and autologous bone marrow transplantation in the treatment of myeloma. Prac Am Soc Clin Oncol 1989; 8: 252
   Google Scholar
• Fermand J P, Levy Y, Gerota J. Treatment of aggressive multiple myeloma by dose-dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989; 73: 20–23
   PubMed Web of Science ®Google Scholar
• Harousseau J L, Milpied N, Garand R. High dose melphalan and autologous bone marrow transplantation in high risk myeloma. Br J Haematol 1987; 67: 493
   PubMed Web of Science ®Google Scholar
• Antman K S, Griffin JD. E, Iias A. Effect of recombined human granulocyte-macrophage colony stimulative factor in chemotherapy induced myelosuppression. N Engl J Med 1988; 319: 593–598
   PubMed Web of Science ®Google Scholar
• Barlogie B, Epstein J, Selvanayagaw P. Plasma cell myeloma–new biological insights and advances in therapy. Blood 1989; 73: 865–879
   PubMed Web of Science ®Google Scholar
• Durie B GM, Russell D H, Salmon S E. Reappraisal of plateau phase in myeloma. Lancet 1980; 2: 65–68
   PubMed Web of Science ®Google Scholar